



Vivimed

For Immediate Release

November 29, 2016

Vivimed's FDF facility in Alathur completed successful USFDA inspection

All of the Company's manufacturing plants focussed on the regulated markets have been inspected with a favourable outcome, over the last two years

Hyderabad, India, November 29, 2016 – Vivimed Labs Limited ("Vivimed" or the Company), a niche Specialty Chemicals and Pharmaceuticals company, announced today that its FDF manufacturing facility located in Alathur, near Chennai has had a favourable outcome post its US Food and Drug Administration (USFDA) inspection. The audit was conducted during the last week of November and concluded on November 28, 2016.

Furthermore, Vivimed obtained ANDA approval for Metronidazole and same is commercialised. During November 2016, the Company acquired ANDA of Zolpidem and the file transfer has successfully been completed. It is expected to be commercialised by Q4 FY2017. Vivimed is on track of its filing targets and has successfully completed 3 ANDA filings during FY2017 and expect one more filing to be completed by Q4 FY2017. These products provide vertical integration with the in-house APIs.

Commenting on the development, **Mr. Santosh Varalwar, Managing Director** said:

"Over the past two years we have received satisfactory outcomes of USFDA inspection for our two plants in Spain, one in Mexico and one in India. For the India plant, this was the second inspection, and we are delighted by the outcome as this is reflection of the efforts of our team to constantly maintain high levels of regulatory compliance. We believe that this satisfactory outcome will support our endeavour to further strengthen our positioning in the global markets. We are on track with our filings pipeline which are expected to bear fruits when these products start to commercialise over the next 18-24 months."

Analyst and Investor Enquiries

Ramesh Challa, CFO
Vivimed Labs Limited

+91 40 2717 6005
ramesh.challa@vivimedlabs.com

Saket Somani
Churchgate Partners

+91 22 6169 5988
Vivimed@churchgatepartnersindia.com

For further information on Vivimed, visit www.vivimedlabs.com

Safe Harbour

This release contains "forward looking statements" including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Vivimed's future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macroeconomic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Vivimed undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.

For VIVIMED LABS LTD.
Ayugundhar

Company Secretary